MA38694A2 - Dérivés thérapeutiquement actifs d'estratriène-thiazole à substitution azote en position 17 en tant qu'inhibiteurs de la 17bêta.-hydroxystéroïde déshydrogénase - Google Patents
Dérivés thérapeutiquement actifs d'estratriène-thiazole à substitution azote en position 17 en tant qu'inhibiteurs de la 17bêta.-hydroxystéroïde déshydrogénaseInfo
- Publication number
- MA38694A2 MA38694A2 MA38694A MA38694A MA38694A2 MA 38694 A2 MA38694 A2 MA 38694A2 MA 38694 A MA38694 A MA 38694A MA 38694 A MA38694 A MA 38694A MA 38694 A2 MA38694 A2 MA 38694A2
- Authority
- MA
- Morocco
- Prior art keywords
- substituted
- inhibitors
- 17beta
- natrium
- therapeutically active
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0036—Nitrogen-containing hetero ring
- C07J71/0042—Nitrogen only
- C07J71/0052—Nitrogen only at position 16(17)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0036—Nitrogen-containing hetero ring
- C07J71/0057—Nitrogen and oxygen
- C07J71/0068—Nitrogen and oxygen at position 16(17)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne des composés de formule (i) et des sel pharmaceutiquement acceptables de ceux-ci, dans laquelle r2 à r7 sont tels que définis dans les revendications. L'invention concerne en outre leur utilisation en tant qu'inhibiteurs de la 17ß-hsd et pour le traitement ou la prévention de maladies ou troubles dépendant des hormones stéroïdes, tels que des maladies ou troubles dépendant des hormones stéroïdiennes exigeant l'inhibition de l'enzyme 17ß-hsd1 et/ou exigeant la réduction de la concentration en estradiol endogène. La présente invention concerne également la préparation des composés susmentionnés et de compositions pharmaceutiques comprenant en tant que principe(s) actif(s) un ou plusieurs des composés susmentionnés ou leurs sels pharmaceutiquement acceptables.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20135694 | 2013-06-25 | ||
PCT/FI2014/050518 WO2014207310A1 (fr) | 2013-06-25 | 2014-06-25 | Dérivés thérapeutiquement actifs d'estratriène-thiazole à substitution azote en position 17 en tant qu'inhibiteurs de la 17bêta.-hydroxystéroïde déshydrogénase |
Publications (2)
Publication Number | Publication Date |
---|---|
MA38694A2 true MA38694A2 (fr) | 2017-12-29 |
MA38694B1 MA38694B1 (fr) | 2020-01-31 |
Family
ID=51220584
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA38694A MA38694B1 (fr) | 2013-06-25 | 2014-06-25 | Dérivés thérapeutiquement actifs d'estratriène-thiazole à substitution azote en position 17 en tant qu'inhibiteurs de la 17bêta.-hydroxystéroïde déshydrogénase |
Country Status (18)
Country | Link |
---|---|
US (1) | US9663549B2 (fr) |
EP (1) | EP3013846B1 (fr) |
JP (1) | JP6556125B2 (fr) |
KR (1) | KR20160042873A (fr) |
CN (1) | CN105518015B (fr) |
AR (1) | AR096729A1 (fr) |
AU (1) | AU2014300894A1 (fr) |
BR (1) | BR112015031846A8 (fr) |
CA (1) | CA2914667A1 (fr) |
EA (1) | EA201690077A1 (fr) |
HK (1) | HK1217495A1 (fr) |
IL (1) | IL242968A0 (fr) |
MA (1) | MA38694B1 (fr) |
MX (1) | MX2015017879A (fr) |
SG (1) | SG11201510251TA (fr) |
TN (1) | TN2015000555A1 (fr) |
TW (1) | TW201534612A (fr) |
WO (1) | WO2014207310A1 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107207562B (zh) * | 2014-12-23 | 2020-03-06 | 佛恩多制药有限公司 | 17β-HSD1抑制剂的前药 |
CN107207561B (zh) * | 2014-12-23 | 2020-03-31 | 佛恩多制药有限公司 | 17β-HSD1–抑制剂的前药 |
CZ307437B6 (cs) | 2016-06-07 | 2018-08-22 | Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. | 15β-substituované deriváty estronu jako selektivní inhibitory 17β-hydroxysteoiddehydrogenáz |
UA126342C2 (uk) * | 2017-06-08 | 2022-09-21 | Форендо Фарма Лтд | 15-бета-[3-пропанамідо]-заміщені естра-1,3,5(10)-трієн-17-он-сполуки і їх 17-оксими для використання в інгібуванні 17-бета-гідроксистероїддегідрогеназ |
SG11202105795XA (en) * | 2018-12-05 | 2021-06-29 | Forendo Pharma Ltd | Estra-1,3,5(10)-triene compounds condensed in position 16(17) with a pyrazole ring as inhibitors of 17-hsd1 |
CN114644673B (zh) * | 2020-12-19 | 2023-12-26 | 上海喀露蓝科技有限公司 | 一种***衍生物、其制备方法及其在医药上的用途 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL343862A1 (en) | 1998-03-11 | 2001-09-10 | Endorech | Inhibitors of type 5 and type 3 17β−hydroxysteroid dehydrogenase and methods for their use |
ATE355279T1 (de) | 1998-08-07 | 2006-03-15 | Novartis Vaccines & Diagnostic | Pyrazole als modulatoren des östrogenrezeptors |
GB9929302D0 (en) | 1999-12-11 | 2000-02-02 | Univ Cardiff | Benzyl tetralins compositions and uses thereof |
JP2004537499A (ja) * | 2000-11-27 | 2004-12-16 | エントレメッド インコーポレイテッド | 抗血管新生薬 |
DK1423381T3 (da) | 2001-09-06 | 2007-05-07 | Schering Corp | 17beta-hydroxysteroid-dehydrogenase type 3-inhibitorer til behandling af androgenafhængige sygdomme |
AR036812A1 (es) | 2001-10-17 | 2004-10-06 | Schering Corp | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de medicamentos para el tratamiento de enfermedades androgeno-dependientes |
US6750248B2 (en) | 2001-11-09 | 2004-06-15 | National University Of Singapore | Methods for preparing an estrogenic preparation and isolated estrogenic compounds from a plant and uses thereof |
CA2506290C (fr) | 2002-11-18 | 2012-04-24 | Schering Corporation | Inhibiteurs de la 17beta-hydroxysteroide deshydrogenase de type 3 utilises pour le traitement de maladies androgeno-dependantes |
JP4585320B2 (ja) | 2002-12-17 | 2010-11-24 | シェーリング コーポレイション | 男性ホルモン依存性疾患の処置のための17β−ヒドロキシステロイドデヒドロゲナーゼ3型インヒビター |
WO2004085345A2 (fr) | 2003-03-21 | 2004-10-07 | Yale University | Esters d'acide carboxylique et d'estradiol substitues en 15$g(a) en tant qu'oestrogenes localement actifs |
GB0306718D0 (en) | 2003-03-24 | 2003-04-30 | Sterix Ltd | Compound |
US7754709B2 (en) | 2003-06-10 | 2010-07-13 | Solvay Pharmaceuticals Bv | Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds |
US7465739B2 (en) | 2003-06-10 | 2008-12-16 | Solvay Pharmaceuticals B.V. | Compounds and their use in therapy |
TWI331154B (en) * | 2003-11-12 | 2010-10-01 | Solvay Pharm Gmbh | Novel 17-hydroxysteroid dehydrogenase type i inhibitors |
US7378426B2 (en) | 2004-03-01 | 2008-05-27 | Bristol-Myers Squibb Company | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
DE102004032673A1 (de) | 2004-07-02 | 2006-01-26 | Schering Ag | Neue 2-substituierte D-Homo-estra-1,3,5(10)-triene als Inhibitoren der 17ß-Hydroxysteroiddehydrogenase Typ 1 |
DE102004032674A1 (de) | 2004-07-02 | 2006-01-26 | Schering Ag | Neue 2-substituierte Estra-1,3,5(10)-trien-17-one als Inhibitoren der 17β-Hydroxysteroiddehydrogenase Typ 1 |
UA89964C2 (ru) | 2004-09-08 | 2010-03-25 | Н.В. Органон | 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ, КОТОРЫЕ ИМЕЮТ СЕЛЕКТИВНУЮ ЭСТРОГЕННУЮ АКТИВНОСТЬ |
CN102796160A (zh) | 2005-05-26 | 2012-11-28 | 索尔瓦药物有限公司 | 17β-HSD1和STS抑制剂 |
US8030298B2 (en) * | 2005-05-26 | 2011-10-04 | Abbott Products Gmbh | 17β-HSD1 and STS inhibitors |
AU2007299010B2 (en) * | 2006-09-19 | 2013-01-31 | Solvay Pharmaceuticals Gmbh | Estratriene derivatives and their uses as 17beta-hydroxysteroid dehydrogenase inhibitors |
US8288367B2 (en) * | 2006-11-30 | 2012-10-16 | Solvay Pharmaceuticals Gmbh | Substituted estratriene derivatives as 17BETA HSD inhibitors |
RU2453554C2 (ru) | 2006-11-30 | 2012-06-20 | Зольвай Фармасьютиклз Гмбх | Замещенные производные эстратриена как ингибиторы 17бета hsd |
-
2014
- 2014-06-25 US US14/392,291 patent/US9663549B2/en active Active
- 2014-06-25 BR BR112015031846A patent/BR112015031846A8/pt not_active IP Right Cessation
- 2014-06-25 CN CN201480046108.2A patent/CN105518015B/zh active Active
- 2014-06-25 MA MA38694A patent/MA38694B1/fr unknown
- 2014-06-25 EP EP14742254.7A patent/EP3013846B1/fr active Active
- 2014-06-25 AU AU2014300894A patent/AU2014300894A1/en not_active Abandoned
- 2014-06-25 SG SG11201510251TA patent/SG11201510251TA/en unknown
- 2014-06-25 TN TN2015000555A patent/TN2015000555A1/en unknown
- 2014-06-25 JP JP2016522679A patent/JP6556125B2/ja active Active
- 2014-06-25 KR KR1020167001998A patent/KR20160042873A/ko not_active Application Discontinuation
- 2014-06-25 WO PCT/FI2014/050518 patent/WO2014207310A1/fr active Application Filing
- 2014-06-25 TW TW103121874A patent/TW201534612A/zh unknown
- 2014-06-25 MX MX2015017879A patent/MX2015017879A/es unknown
- 2014-06-25 CA CA2914667A patent/CA2914667A1/fr not_active Abandoned
- 2014-06-25 EA EA201690077A patent/EA201690077A1/ru unknown
- 2014-06-25 AR ARP140102399A patent/AR096729A1/es unknown
-
2015
- 2015-12-06 IL IL242968A patent/IL242968A0/en unknown
-
2016
- 2016-05-16 HK HK16105581.6A patent/HK1217495A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CA2914667A1 (fr) | 2014-12-31 |
EA201690077A1 (ru) | 2016-09-30 |
US9663549B2 (en) | 2017-05-30 |
AU2014300894A1 (en) | 2016-01-28 |
AR096729A1 (es) | 2016-01-27 |
JP6556125B2 (ja) | 2019-08-07 |
CN105518015B (zh) | 2017-09-15 |
SG11201510251TA (en) | 2016-01-28 |
TN2015000555A1 (en) | 2017-04-06 |
BR112015031846A2 (pt) | 2017-07-25 |
MA38694B1 (fr) | 2020-01-31 |
EP3013846A1 (fr) | 2016-05-04 |
TW201534612A (zh) | 2015-09-16 |
BR112015031846A8 (pt) | 2018-03-06 |
HK1217495A1 (zh) | 2017-01-13 |
KR20160042873A (ko) | 2016-04-20 |
WO2014207310A1 (fr) | 2014-12-31 |
US20170081357A1 (en) | 2017-03-23 |
MX2015017879A (es) | 2017-03-01 |
EP3013846B1 (fr) | 2017-08-09 |
IL242968A0 (en) | 2016-02-01 |
JP2016523886A (ja) | 2016-08-12 |
CN105518015A (zh) | 2016-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA38694A2 (fr) | Dérivés thérapeutiquement actifs d'estratriène-thiazole à substitution azote en position 17 en tant qu'inhibiteurs de la 17bêta.-hydroxystéroïde déshydrogénase | |
MA40111A1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
MA53399B1 (fr) | Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine | |
MA35348B1 (fr) | 4-imidazopyridazin-1-yl-benzamides et 4-imidazotriazin-1-yl-benzamides en tant qu'inhibiteurs de btk | |
MA33239B1 (fr) | 3h-imidazo [4,5-c] pyridine-6-carboxamides en tant qu'anti-inflammatoires | |
MA44674A (fr) | Inhibiteurs de bromodomaine | |
MA37850A1 (fr) | Inhibiteurs de nep pour le traitement de maladies caractérisées par un agrandissement atrial ou une remodélisation atriale | |
MA45598B1 (fr) | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda | |
MA34083B1 (fr) | Compositions pharmaceutques de composé spiro-oxindole pour administration topique et leur utilisation en tant qu'agents thérapeutiques | |
TN2013000393A1 (fr) | Derives de la pyrazolospirocetone pour une utilisation comme inhibiteurs de l'acetyl-coa carboxylase | |
MA43052B1 (fr) | Inhibiteurs de la kallicréine plasmatique humaine | |
MA37763B1 (fr) | Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1 | |
MA43913A (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique | |
MA46268B1 (fr) | Dérivés de 5-[2-(pyridin-2-ylamino)-1 ,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-one et leur utilisation en tant qu'inhibiteurs doubles de phosphatidylinositol 3-kinase delta & gamma | |
MX2021009539A (es) | Derivado del profarmaco 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y aplicacion del mismo en medicina. | |
EA202191955A1 (ru) | Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы | |
MA33563B1 (fr) | 5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl | |
MA38358A1 (fr) | Formulations de composés organiques | |
MA39186A1 (fr) | Dérivés de [1,2,4]triazolo[1,5-a]pyrimidine utilisés comme inhibiteurs du protéasome des protozoaires pour le traitement de maladies parasitaires comme la leishmaniose | |
MA39447A1 (fr) | (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
EA201992826A1 (ru) | 15бета-[3-пропанамидо]-замещенные эстра-1,3,5(10)-триен-17-оны и их 17-оксимы для применения в ингибировании 17бета-гидроксистероиддегидрогеназ | |
MA53372B1 (fr) | Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine | |
MA33979B1 (fr) | Piperazines en tant qu'agents antipaludiques | |
MA46778B1 (fr) | Composition intranasale comprenant de la bétahistine | |
EA202191531A1 (ru) | Терапевтически активные стероидные производные |